Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes-Reference-Cited by-同舟云学术

Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

Published:2022-01 Issue:1 Volume:22 Page:24-33
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Casasnovas Rene-Olivier,Follows George,Zijlstra Josee M.,Vermaat Joost S.P.,Kalakonda Nagesh,Choquet Sylvain,Neste Eric Van Den,Hill Brian,Thieblemont Catherine,Cavallo Federica,la Cruz Fatima De,Kuruvilla John,Hamad Nada,Jaeger Ulrich,Caimi Paolo F.,Gurion Ronit,Warzocha Krzysztof,Bakhshi Sameer,Sancho Juan-Manuel,Schuster Michael,Egyed Miklos,Offner Fritz,Vassilakopoulos Theodoros P.,Samal Priyanka,Ku Matthew,Ma Xiwen,Chamoun Kamal,Shah Jatin,Canales Miguel,Maerevoet Marie,Shacham Sharon,Kauffman Michael G.,Goy Andre

Funder

Karyopharm Therapeutics Inc

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference41 articles.

1. The 2016 revision of the World Health Organization classification of lymphoid neoplasms;Swerdlow;Blood,2016

2. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity;Sehn;Blood,2015

3. Management of relapsed/refractory DLBCL;Sarkozy;Best Pract Res Clin Haematol,2018

4. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Tilly;Ann Oncol,2015

5. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte;Coiffier;Blood,2010

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel—and Not So Novel—Inhibitors of the Multifunctional CRM1 Protein;Oncology Reviews;2024-08-05

2. Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas;Cancers;2024-06-17

3. Selinexor and Other Selective Inhibitors of Nuclear Export (SINEs)—A Novel Approach to Target Hematologic Malignancies and Solid Tumors;Drugs and Drug Candidates;2023-05-31

4. Targeting Nuclear Protein Transport with XPO Inhibitors in Lymphoma;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

5. Sequencing therapy in relapsed DLBCL;Hematology;2022-12-09